Soc. Generale Knock-Out GNMSF/ DE000CL9G895 /
2024-05-14 9:23:17 AM | Chg.+0.58 | Bid8:36:02 PM | Ask8:36:02 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.70EUR | +18.59% | 3.55 Bid Size: 900 |
3.79 Ask Size: 900 |
Genmab A/S | 1,771.3816 - | 2078-12-31 | Call |
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
2021-09-20
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
2021-07-21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
GlobeNewswire
2021-06-22
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumu...